

Resource Summary Report

Generated by NIF on Jul 29, 2026

PE/Cyanine7 anti-mouse IFN-?

RRID:AB_2295770

Type: Antibody

Proper Citation

BioLegend Cat# 505826, RRID:AB_2295770

Antibody Information

URL: http://antibodyregistry.org/AB_2295770

Proper Citation: BioLegend Cat# 505826, RRID:AB_2295770

Target Antigen: IFN-gamma

Host Organism: rat

Clonality: monoclonal

Comments: Applications: ICFC

Antibody Name: PE/Cyanine7 anti-mouse IFN-?

Description: This monoclonal targets IFN-gamma

Target Organism: mouse

Clone ID: Clone XMG1.2

Antibody ID: AB_2295770

Vendor: BioLegend

Catalog Number: 505826

Alternative Catalog Numbers: 505825

Record Creation Time: 20250819T233320+0000

Record Last Update: 20250820T054223+0000

Ratings and Alerts

No rating or validation information has been found for PE/Cyanine7 anti-mouse IFN-?.

No alerts have been found for PE/Cyanine7 anti-mouse IFN-?.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 100 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Meitei HT, et al. (2026) CCL20-CCR6 signaling alters the metabolic reprogramming to promote the pathogenic Th17 cell differentiation. *iScience*, 29(1), 114385.

Heaton AR, et al. (2026) Divergent role of CD8 T cells with distinct metabolic phenotypes during curative radio-immunotherapy in hot versus cold tumors. *bioRxiv : the preprint server for biology*.

Xie M, et al. (2025) Tumor-resident probiotic *Clostridium butyricum* improves aPD-1 efficacy in colorectal cancer models by inhibiting IL-6-mediated immunosuppression. *Cancer cell*.

Zeng Q, et al. (2025) Gut microbiota-driven pathogenic Th17 cells mediated autoimmune epididymo-orchitis in a mouse model of colitis. *iScience*, 28(5), 112508.

Huang C, et al. (2025) Priming with DNMT Inhibitors Potentiates PD-1 Immunotherapy by Triggering Viral Mimicry in Relapsed/Refractory NK/T-cell Lymphoma. *Cancer discovery*, 15(12), 2450.

Xu C, et al. (2025) Tailoring an intravenously injectable oncolytic virus for augmenting radiotherapy. *Cell reports. Medicine*, 6(5), 102078.

van der Heide V, et al. (2025) Prolonged but finite antigen presentation promotes reversible defects of "helpless" memory CD8+ T cells. *Immunity*, 58(7), 1742.

Li Q, et al. (2025) Stromal Cell-Mast Cell Communication Orchestrates Anti-Viral Immunity in the Meninges. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, e14842.

Newsome RC, et al. (2025) Microbial-derived immunostimulatory small molecule augments anti-PD-1 therapy in lung cancer. *Cell reports. Medicine*, 102519.

Song H, et al. (2025) Targeting tumor monocyte-intrinsic PD-L1 by rewiring STING signaling and enhancing STING agonist therapy. *Cancer cell*, 43(3), 503.

Wei H, et al. (2025) AKR1D1 suppresses liver cancer progression by promoting bile acid metabolism-mediated NK cell cytotoxicity. *Cell metabolism*, 37(5), 1103.

Lamorte S, et al. (2025) Lymph node macrophages drive immune tolerance and resistance to cancer therapy by induction of the immune-regulatory cytokine IL-33. *Cancer cell*, 43(5), 955.

Humblin E, et al. (2025) The costimulatory molecule ICOS limits memory-like properties and function of exhausted PD-1+CD8+ T cells. *Immunity*, 58(8), 1966.

Clark ML, et al. (2025) Mitochondrial complex IV remodeling in tumor-associated macrophages amplifies interferon signaling and promotes anti-tumor immunity. *Immunity*, 58(7), 1670.

Wang B, et al. (2025) Targeting CTGF overcomes resistance to CSF1R inhibitors by preventing CAF activation in colorectal cancer. *Cell reports. Medicine*, 6(12), 102480.

Cohen JA, et al. (2025) KMT2D coordinates antiviral CD4+ T cell responses through opposing effects on T follicular helper and cytotoxic gene expression. *Cell reports*, 44(6), 115775.

Benmebarek MR, et al. (2025) Anti-vascular endothelial growth factor treatment potentiates immune checkpoint blockade through a BAFF- and IL-12-dependent reprogramming of the TME. *Immunity*, 58(4), 926.

Guo C, et al. (2025) In situ extended immune activation instantly after tumor resection by oncolytic virus controls postoperative tumor recurrence. *Cell reports. Medicine*, 6(10), 102399.

Li D, et al. (2025) SOSTDC1 downregulation in CD4+ T cells confers protection against obesity-induced insulin resistance. *Cell reports*, 44(4), 115496.

Calôba C, et al. (2025) Systemic 4-1BB stimulation augments extrafollicular memory B cell formation and recall responses during *Plasmodium* infection. *Cell reports*, 44(4), 115528.